Exelixis says Phase 3 CONTACT-03 study did not meet its primary endpoint

Exelixis announced that the phase 3 CONTACT-03 study did not meet its primary endpoint of progression-free survival. CONTACT-03 evaluated cabozantinib in combination with atezolizumab versus cabozantinib alone in patients with locally advanced or metastatic clear cell or non-clear cell renal cell carcinoma who progressed during or after immune checkpoint inhibitor therapy. The safety profile of the combination of cabozantinib and atezolizumab observed in the trial was consistent with the known safety profiles for each single agent, and no new safety signals were identified with the combination. Detailed findings will be presented at an upcoming medical meeting.